Quince Therapeutics (QNCX) Non-Current Assets (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Non-Current Assets of $1.0 million for Q1 2026, down 98.58% year-over-year from $73.3 million in Q1 2025, and down 98.52% quarter-over-quarter from $70.6 million in Q4 2025.
Quince Therapeutics (QNCX) Non-Current Assets (2018 - 2026) Analysis & Trends
Quince Therapeutics' Non-Current Assets history runs 9 years deep, the most recent figure standing at $1.0 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 98.58% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $232.2 million (down 19.89% YoY), while the FY2025 annual figure was $70.6 million, changed 0.26% from the prior year.
- Non-Current Assets for Q1 2026 stood at $1.0 million, down from $70.6 million in the prior quarter.
- The five-year high for Non-Current Assets was $90.5 million in Q4 2023, with the low at $213000.0 in Q3 2023.
- The 5-year median for Non-Current Assets is $70.4 million (2024), against an average of $44.9 million.
- The sharpest annual moves came in 2024 and 2026: Non-Current Assets soared 35017.84% in 2024, then plunged 98.58% in 2026.
- Quince Therapeutics' Non-Current Assets stood at $10.2 million in 2022, then jumped by 790.18% to $90.5 million in 2023, then slipped by 22.13% to $70.4 million in 2024, then climbed by 0.26% to $70.6 million in 2025, then sank by 98.52% to $1.0 million in 2026.
- Business Quant data shows QNCX's Non-Current Assets at $1.0 million in Q1 2026, $70.6 million in Q4 2025, and $80.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | 584,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.04 Mn |
| Dec 31, 2025 | 70.63 Mn |
| Sep 30, 2025 | 80.70 Mn |
| Jun 30, 2025 | 79.87 Mn |
| Mar 31, 2025 | 73.26 Mn |
| Dec 31, 2024 | 70.44 Mn |
| Sep 30, 2024 | 74.80 Mn |
| Jun 30, 2024 | 71.39 Mn |
| Mar 31, 2024 | 88.85 Mn |
| Dec 31, 2023 | 90.46 Mn |
| Sep 30, 2023 | 213,000.00 |
| Jun 30, 2023 | 288,000.00 |
| Mar 31, 2023 | 827,000.00 |
| Dec 31, 2022 | 10.16 Mn |
| Sep 30, 2022 | 11.50 Mn |
| Jun 30, 2022 | 18.49 Mn |
| Mar 31, 2022 | 19.78 Mn |
| Dec 31, 2021 | 21.56 Mn |
| Sep 30, 2021 | 27.99 Mn |
| Jun 30, 2021 | 25.55 Mn |